medigraphic.com

2018, Número 1

<< Anterior Siguiente >>

Rev Hematol Mex 2018; 19 (1)


Leucemia mieloide aguda

Leyto-Cruz F

Idioma: Español
Referencias bibliográficas: 103
Paginas: 24-40
Archivo PDF: 341.14 Kb.


RESUMEN

La leucemia mieloide aguda es la leucemia aguda más común en adultos. Los factores de riesgo de su aparición son muy variados e incluyen aspectos genéticos y adquiridos. En México no se cuenta con información confiable respecto de esta enfermedad, la incidencia, la prevalencia y la mortalidad son datos que no se pueden considerar exactos, aunque se han realizado diferentes esfuerzos locales o regionales para obtener información epidemiológica. Por ello se revisa la información disponible internacional y nacional para ofrecer una visión más cercana a la realidad nacional. La tasa de mortalidad en México para 2008 debido a leucemias (linfoide, mieloide, monocítica y otras) estimada por la Secretaría de Salud fue de 3.5 por cada 100,000 habitantes, mientras que Globocan reportó para 2012 una tasa de mortalidad ajustada por edad de 3.7 por cada 100,000 habitantes. Este artículo revisa los procedimientos de diagnóstico de la enfermedad, los criterios de pronóstico y los diferentes tratamientos disponibles en México en las fases de inducción y consolidación.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control CCC 2008;19(4):379-390.

  2. Stone RM, O’Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematol Am Soc Hematol Educ Program 2004:98-117.

  3. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341(14):1051-1062.

  4. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet Lond Engl 2013;381(9865):484-495.

  5. García-Vidrios MV, Lomelí-Guerrero A, Sánchez-Valle E, Gómez-Almaguer D. Tratamiento de las leucemias agudas del adulto I. Avances en el manejo de la leucemia aguda linfoblástica del adulto II. Tratamiento estándar de la leucemia mieloide aguda del adulto III. Avances en el tratamiento de la leucemia aguda mieloblástica. Gac Méd Méx 2002;138(S1):94-101.

  6. De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J 2016;6(7):e441.

  7. Aguilar López L, León Cantú RE, Pérez Lozano U, Montaño Figueroa EH, Terreros Muñoz E, Martínez Murillo C. Guía de Práctica Clínica; Diagnóstico y tratamiento de la leucemia mieloide aguda. 2010.

  8. Licht JD, Sternberg DW. The molecular pathology of acute myeloid leukemia. Hematol Am Soc Hematol Educ Program 2005:137-142.

  9. Tonks A, Pearn L, Musson M, Gilkes A, Mills KI, Burnett AK, et al. Transcriptional dysregulation mediated by RUNX1- RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. Leukemia 2007;21(12):2495-2505.

  10. Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012;366(12):1079-1089.

  11. The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013;368(22):2059-2074.

  12. Milanés Roldán MT, Losada Buchillón R, Hernández Ramírez P, Agramonte Llanes O, Rosell Monzón E. Aspectos clínicos y epidemiológicos de la leucemia mieloide aguda en el anciano. Rev Cuba Hematol Inmunol Hemoter 2002;18(1):0-0.

  13. Tamamyan G, Kadia T, Ravandi F, Borthakur G, Cortes J, Jabbour E, et al. Frontline treatment of acute myeloid leukemia in adults. Crit Rev Oncol Hematol 2017;110:20-34.

  14. Merino A. Clasificación de las leucemias agudas mieloides. Rev Lab Clínico 2010:139-147.

  15. American Cancer Society. ¿Cómo se clasifica la leucemia mieloide aguda? 2016.

  16. Jaffe ES, Harris N, Stein H, Vardiman JW, editors. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues: WHO Classification of Tumours. 3rd ed. Lyon: IARC Press; 2001.

  17. Vardiman JW, Thiele J, Arber DA, Brunning RD, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114(5):937-951.

  18. Gupta G, Singh R, Kotasthane DS, Kotasthane VD. Myelodysplastic syndromes/neoplasms: recent classification system based on World Health Organization Classification of Tumors - International Agency for Research on Cancer for Hematopoietic and Lymphoid Tissues. J Blood Med 2010;1:171-182.

  19. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117(19):5019-5032.

  20. Arber DA, Orazi A, Hasserjian R, Thiele J, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127(20):2391-2405.

  21. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116(3):354-365.

  22. Howell DA, Smith AG, Jack A, Patmore R, Macleod U, Mironska E, et al. Time-to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: a report from the Haematological Malignancy Research Network. BMC Hematol 2013;13(1):9.

  23. National Collaborating Centre for Primary Care. Referral guidelines for suspected cancer. 2005.

  24. Rozovski U, Ohanian M, Ravandi F, Garcia-Manero G, Faderl S, Pierce S, et al. Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia. Leuk Lymphoma 2015;56(5):1392-1397.

  25. Röllig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood 2015;125(21):3246-3252.

  26. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide, 2012. Hyperlink “http:// www.globocan.iarc.fr”www.globocan.iarc.fr. Accessed 21 September 2014.

  27. Sant M, Allemani C, Tereanu C, De Angelis R, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010;116(19):3724-3734.

  28. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106(4):1154-1163.

  29. Casasnovas RO, Slimane FK, Garand R, Faure GC, Campos L, Deneys V, et al. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome. Leukemia 2003;17(3):515-527.

  30. National Cancer Institute. SEER Cancer Stat Facts: Acute Myeloid Leukemia. Natl Cancer Inst.

  31. Estey E, Döhner H. Acute myeloid leukaemia. Lancet Lond Engl 2006;368(9550):1894-1907.

  32. Fay MP, Pfeiffer R, Cronin KA, Le C, Feuer EJ. Ageconditional probabilities of developing cancer. Stat Med 2003;22(11):1837-1848.

  33. Pinto A, Zagonel V, Ferrara F. Acute myeloid leukemia in the elderly: biology and therapeutic strategies. Crit Rev Oncol Hematol 2001;39(3):275-287.

  34. Gutiérrez-Aguirre CH, González-Leal XJ, Herrera-Pérez F del C, Zacarías-Reyes BC, Herrera-Rojas MÁ, Gómez-Almaguer D. Trasplante autólogo de células hematopoyéticas en leucemia mieloide aguda. Rev Hematol 2014;15(3):87-94.

  35. Gómez-Almaguer D, Marcos-Ramírez ER, Montaño-Figueroa EH, Ruiz-Argüelles GJ, et al. Acute leukemia characteristics are different around the world: the Mexican perspective. Clin Lymphoma Myeloma Leuk 2017;17(1):46-51.

  36. González-Salas WM, Olarte-Carrillo I, Gutiérrez-Romero M, Montaño-Figueroa EH, Martínez-Murillo C, Ramos- Peñafiel CO. Frecuencia de leucemias agudas en un hospital de referencia. Rev Médica Inst Mex Seguro Soc 2012;50(2):167-171.

  37. Buitrón-Santiago N, Arteaga-Ortiz L, Rosas-López A, Aguayo Á, López-Karpovitch X, Crespo-Solís E. Experiencia del INCMNSZ en pacientes adultos con leucemia mieloide aguda. Cohorte 2003-2008. Rev Investig Clínica 2010;62(2):100-108.

  38. Verdejo B, Leyto Cruz F, Milan AI. 1215: Incidencia de leucemias agudas en el Hospital Juárez de México. Rev Hematol 2017;18(supl. 1):S141.

  39. Mejía-Aranguré JM, Núñez-Enríquez JC, Fajardo-Gutiérrez A, Rodríguez-Zepeda M del C, Martín-Trejo JA, Duarte-Rodríguez DA, et al. Epidemiología descriptiva de la leucemia mieloide aguda (LMA) en niños residentes de la Ciudad de México: reporte del Grupo Mexicano Interinstitucional para la Identificación de las Causas de la Leucemia en Niños. Gac Méd Méx 2016;152(S2):66-77.

  40. Subsecretaría de prevención y promoción de la salud. Dirección general de epidemiología. Perfil epidemiológico de los tumores malignos en México. 2011.

  41. Secretaría de Salud DG de I en S. Bases de Datos Estándar Egresos Hospitalarios.

  42. Fey MF, Buske C, on behalf of the ESMO Guidelines Working Group. Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(suppl 6):vi138-vi143.

  43. International Agency for Research on Cancer. Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence worldwide in 2012. Fact Sheets by Population - Mexico.

  44. Hulegårdh E, Nilsson C, Lazarevic V, Garelius H, Antunovic P, Rangert Derolf Å, et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol 2015;90(3):208-214.

  45. Nacho-Vargas KA, Sánchez-Valle E. Leucemias del adulto I. Introducción II. Avances en la biología molecular de la leucemia linfoblástica aguda III. Resultados del tratamiento de la leucemia mieloide aguda en recaida. Gac Méd Méx 2003;139(Supl. 2):106-112.

  46. Pulte D, Gondos A, Brenner H. Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica 2008;93(4):594-600.

  47. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999;94(3):1086-1099.

  48. Zagonel V, Fratino L, Sacco C, Babare R, et al. Reducing chemotherapy-associated toxicity in elderly cancer patients. Cancer Treat Rev 1996;22(3):223-244.

  49. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 1998;92(7):2322-2333.

  50. Röllig C, Bornhäuser M, Thiede C, Taube F, Kramer M, Mohr B, et al. Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System. J Clin Oncol 2011;29(20):2758-2765.

  51. Kayser S, Schlenk RF, Londono MC, Breitenbuecher F, Wittke K, Du J, et al. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood 2009;114(12):2386-2392.

  52. Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mrózek K, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol 2012;30(7):742-750.

  53. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010;363(25):2424-2433.

  54. Sehgal AR, Gimotty PA, Zhao J, Hsu J-M, Daber R, Morrissette JD, et al. DNMT3A Mutational status affects the results of dose-escalated induction therapy in acute myelogenous leukemia. Clin Cancer Res Off J Am Assoc Cancer Res 2015;21(7):1614-1620.

  55. Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia 2008;22(8):1539-1541.

  56. Döhner K, Schlenk RF, Habdank M, Scholl C, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005;106(12):3740-3746.

  57. Fasan A, Haferlach C, Alpermann T, Jeromin S, Grossmann V, Eder C, et al. The role of different genetic subtypes of CEBPA mutated AML. Leukemia 2014;28(4):794-803.

  58. Kühnl A, Grimwade D. Molecular markers in acute myeloid leukaemia. Int J Hematol 2012;96(2):153-163.

  59. Mrózek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007;109(2):431-448.

  60. Pulsoni A, Iacobelli S, Bernardi M, Borgia M, Camera A, Cantore N, et al. M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience. Haematologica 2008;93(7):1025-1032.

  61. Estey EH. Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol 2013;88(4):318-327.

  62. Döhner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115(3):453-474.

  63. National Comprehensive Cancer Network (NCCN) Clinical practice guide-lines in oncology. Acute myeloid leukemia. Version 2. 2016. 2016.

  64. Erba HP. Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy. Leuk Res 2015;39(2):183-191.

  65. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361(13):1249-1259.

  66. Estey EH. Acute myeloid leukemia: 2014 update on risk-stratification and management. Am J Hematol 2014;89(11):1063-1081.

  67. Tomás JF, Román A, Subirá D, Vizcarra E, Llamas P, Fernández de Velasco J. Enfermedad mínima residual. Significado de la remisión en enfermedades oncohematológicas. Haematologica (Ed esp). 2004;89(Supl. E1):50-56.

  68. Sajaroff E, Rubio P, Medina A, Sanz M, Alonso C, Bernasconi A, et al. Determinación de enfermedad mínima residual en leucemias agudas. Med Infant 2012;XIX(4):287-295.

  69. Buccisano F, Maurillo L, Gattei V, Del Poeta G, Del Principe MI, Cox MC, et al. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia 2006;20(10):1783-1789.

  70. Venditti A, Buccisano F, Del Poeta G, Maurillo L, Tamburini A, Cox C, et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000;96(12):3948-3952.

  71. Freeman SD, Virgo P, Couzens S, Grimwade D, Russell N, Hills RK, et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol 2013;31(32):4123-4131.

  72. Jacobsohn DA, Tse WT, Chaleff S, Rademaker A, Duerst R, Olszewski M, et al. High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival. Br J Haematol 2009;146(6):669-674.

  73. Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol 2011;29(9):1190-1197.

  74. Rossi G, Carella AM, Minervini MM, di Nardo F, Waure C de, Greco MM, et al. Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: a comparison between multiparameter flow cytometry and Wilms’ tumor 1 expression. Leuk Res 2015;39(2):138-143.

  75. Grimwade D, Freeman SD. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”? Blood 2014;124(23):3345-3355.

  76. Kohlmann A, Nadarajah N, Alpermann T, Grossmann V, Schindela S, Dicker F, et al. Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease. Leukemia 2014;28(1):129-137.

  77. Saultz JN, Garzon R. Acute myeloid leukemia: A concise review. J Clin Med 2016;5(3).

  78. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014;506(7488):328-333.

  79. Cassileth PA, Harrington DP, Hines JD, Oken MM, Mazza JJ, McGlave P, et al. Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol Off J Am Soc Clin Oncol 1988;6(4):583-587.

  80. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129(4):424-447.

  81. Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 2005;103(8):1652-1658.

  82. Cornelissen JJ, van Putten WLJ, Verdonck LF, Theobald M, Jacky E, Daenen SMG, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLAidentical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007;109(9):3658-3666.

  83. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009;301(22):2349-2361.

  84. Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM, et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992;79(8):1924-1930.

  85. Burnett AK, Goldstone A, Hills RK, Milligan D, Prentice A, Yin J, et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol Off J Am Soc Clin Oncol 2013;31(10):1293-1301.

  86. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, et al. A randomized investigation of highdose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996;88(8):2841-2851.

  87. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998;58(18):4173-4179.

  88. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman PP, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 2001;98(3):548-553.

  89. Wahlin A, Markevärn B, Golovleva I, Nilsson M. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol 2001;115(1):25-33.

  90. Prébet T, Boissel N, Reutenauer S, Thomas X, Delaunay J, Cahn J-Y, et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. J Clin Oncol Off J Am Soc Clin Oncol 2009;27(28):4747-4753.

  91. Hassanein M, Atenafu EG, Schuh AC, Yee KWL, Minden MD, Schimmer AD, et al. High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission. Leuk Res 2013;37(5):556-560.

  92. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331(14):896-903.

  93. Yan P, Frankhouser D, Murphy M, Tam H-H, Rodriguez B, Curfman J, et al. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood 2012;120(12):2466-2474.

  94. Maurillo L, Venditti A, Spagnoli A, Gaidano G, Ferrero D, Oliva E, et al. Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program. Cancer 2012;118(4):1014-1022.

  95. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10(3):223-232.

  96. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol Off J Am Soc Clin Oncol 2002;20(10):2429-2440.

  97. Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 2015;126(3):291-299.

  98. Kadia TM, Ravandi F, Cortes J, Kantarjian H. New drugs in acute myeloid leukemia. Ann Oncol 2016;27(5):770-778.

  99. Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol 2015;16(16):1691-1699.

  100. Serve H, Krug U, Wagner R, Sauerland MC, Heinecke A, Brunnberg U, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol Off J Am Soc Clin Oncol 2013;31(25):3110-3118.

  101. Brodská B, Fuchs O, Otevřelová P, Salek C, Kuželová K. PD-L1 Is Frequently Expressed in Acute Myeloid Leukemia Patients with Leukocytosis. Blood 2016;128(22):5229.

  102. Daver N, Basu S, García Manero G, Cortes J, et al. Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML). 2016.

  103. Przepiorka D, Deisseroth A, Farrell AT. Acute myeloid leukemia response measures other than complete remission. J Clin Oncol Off J Am Soc Clin Oncol 2015;33(31):3675-3676.




2020     |     www.medigraphic.com